Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) and Soligenix (OTC:SNGX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Jazz Pharmaceuticals PLC and Soligenix, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals PLC 0 5 16 0 2.76
Soligenix 0 0 2 0 3.00

Jazz Pharmaceuticals PLC presently has a consensus target price of $181.71, indicating a potential upside of 33.15%. Soligenix has a consensus target price of $8.00, indicating a potential upside of 263.64%. Given Soligenix’s stronger consensus rating and higher possible upside, analysts plainly believe Soligenix is more favorable than Jazz Pharmaceuticals PLC.

Profitability

This table compares Jazz Pharmaceuticals PLC and Soligenix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals PLC 23.58% 22.92% 10.07%
Soligenix -233.27% -196.47% -122.14%

Insider & Institutional Ownership

88.9% of Jazz Pharmaceuticals PLC shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Jazz Pharmaceuticals PLC and Soligenix’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Jazz Pharmaceuticals PLC $1.49 billion 5.50 $396.83 million $6.07 22.48
Soligenix N/A N/A N/A ($0.16) -13.75

Jazz Pharmaceuticals PLC has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals PLC, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Jazz Pharmaceuticals PLC has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Soligenix has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.

Summary

Jazz Pharmaceuticals PLC beats Soligenix on 8 of the 11 factors compared between the two stocks.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.